RecruitingNot Applicable

Efficacy of Xenograft Alone or Mixed With Arginyl-Glycyl-Aspartic Acid (RGD) in Horizontal Ridge Augmentation With Split-crest Technique for Implant Placement

Egypt18 participantsStarted 2023-08-01

Plain-language summary

The aim of the present study is to evaluate the efficacy of xenograft alone or xenograft mixed with Arginylglycylaspartic acid (RGD) , in horizontal ridge augmentation with split-crest technique, for implant placement.

Who can participate

Age range18 Years – 30 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Adults (age 18-30) exhibiting initial insufficiently bone width.
✓. Patients with good oral hygiene.
✓. Patients must be free from systemic diseases that may influence the outcome of the therapy.
✓. Patients with bony horizontal defects alone, Class III \& IV.

Exclusion criteria

✕. Heavy smokers.
✕. Patient treated by immunosuppressive chemotherapy or radio therapy,
✕. Allergy to any material or medication used in the study.
✕. Pregnant females.

What they're measuring

ISQ measurement for implant stability

Timeframe: At time of surgery, at loading and 3 months after loading.

Trial details

NCT IDNCT06585852

SponsorAl-Azhar University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2024-09-01

Contact for this trial

Mahmoud Taha, PHD

01225864104 info@azhar.edu.eg

View on ClinicalTrials.gov More Implant Dentistry trials